XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
This new facility strengthens Latin America as a collaborative hub
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
These findings follow positive Phase 3 results presented earlier this year
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Subscribe To Our Newsletter & Stay Updated
